Phaseline

Companies › FutureGen Biopharmaceutical (Beijing)

FutureGen Biopharmaceutical (Beijing): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
M108 monoclonal antibody
anti-CLDN18.2 monoclonal antibody
CLDN18Phase 3Locally Advanced Unresectable or Metastatic Gastric CancerJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06177041M108 monoclonal antibodyPhase 3Locally Advanced Unresectable or Metastatic Gastric CancerOncologyJan 2027

Targets

CLDN18 (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Biokin (Shanghai) Biopharmaceutical Transcenta Therapeutics (Hangzhou) Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou)

Companies built like this

Suzhou Immunofoco Biotechnology LaNova Medicines Zhejiang Alentis Therapeutics NingBo Junyan Hongshi Biosciences Biokin (Shanghai) Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.